## William Small

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3172932/publications.pdf

Version: 2024-02-01

		126907	88630
145	5,316	33	70
papers	citations	h-index	g-index
145	145	145	5698
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016. Brachytherapy, 2022, 21, 12-21.	0.5	3
2	Driving accountable care with brachytherapy. Brachytherapy, 2022, 21, 4-5.	0.5	0
3	Evaluation of sociodemographic and baseline patient characteristic differences in cervical cancer patients treated with either external beam or brachytherapy boost. Brachytherapy, 2022, 21, 22-28.	0.5	2
4	Response to letter to the editor. Brachytherapy, 2022, , .	0.5	0
5	Treatment of cervical cancer: overcoming challenges in access to brachytherapy. Expert Review of Anticancer Therapy, 2022, 22, 353-359.	2.4	8
6	Management of stage I and II cervical cancer: a review. International Journal of Gynecological Cancer, 2022, 32, 216-224.	2.5	3
7	ACR-ABS-ASTRO Practice Parameter for the Performance of Low-Dose-Rate Brachytherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, Publish Ahead of Print, 243-248.	1.3	1
8	Ripk3 signaling regulates HSCs during stress and represses radiation-induced leukemia in mice. Stem Cell Reports, 2022, 17, 1428-1441.	4.8	6
9	Risk-Stratified Intraoperative Radiation Therapy as a Definitive Adjuvant Radiation Therapy Modality for Women With Early Breast Cancer. Practical Radiation Oncology, 2022, 12, 320-323.	2.1	2
10	Intraoperative radiation therapy for locally advanced and recurrent head and neck cancer Journal of Clinical Oncology, 2022, 40, 6058-6058.	1.6	1
11	Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274) Journal of Clinical Oncology, 2022, 40, 5531-5531.	1.6	0
12	Equity in Radiation Oncology Trials: from Knowledge Generation to Clinical Translation. International Journal of Radiation Oncology Biology Physics, 2022, 113, 511-512.	0.8	7
13	Cervical cancer in Eastern Europe: review and proceedings from the Cervical Cancer Research Conference. International Journal of Gynecological Cancer, 2021, 31, ijgc-2020-001652.	2.5	7
14	NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update. International Journal of Radiation Oncology Biology Physics, 2021, 109, 413-424.	0.8	70
15	Potential Significant Changes in Nuclear Regulatory Commission Policies Regarding Training and Experience Requirements for the Use of Radiopharmaceuticals. Journal of the American College of Radiology, 2021, 18, 312-317.	1.8	2
16	Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines. International Journal of Radiation Oncology Biology Physics, 2021, 109, 186-200.	0.8	8
17	Dosimetric assessment of brass mesh bolus and transparent polymer-gel type bolus for commonly used breast treatment delivery techniques. Medical Dosimetry, 2021, 46, e10-e14.	0.9	5
18	ACR Appropriateness Criteria® Staging and Follow-up of Vulvar Cancer. Journal of the American College of Radiology, 2021, 18, S212-S228.	1.8	4

#	Article	IF	Citations
19	Paclitaxel versus docetaxel-based neoadjuvant chemotherapy and risk of lymphedema in breast cancer patients Journal of Clinical Oncology, 2021, 39, e12620-e12620.	1.6	O
20	Uterine perforation during brachytherapy for cervical cancer: Complications, outcomes, and best practices for forward treatment planning and management. Brachytherapy, 2021, 20, 557-564.	0.5	6
21	Psychological Treatment for Patients Receiving Radiation: Results of NRG Oncology/RTOG 0841. International Journal of Radiation Oncology Biology Physics, 2021, 110, 962-972.	0.8	2
22	Radiation Toxicity in Patients With Collagen Vascular Disease: A Meta-Analysis of Case-Control Studies. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1214-1226.	0.8	7
23	ACR–ABS–ASTRO practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy. Brachytherapy, 2021, 20, 1071-1082.	0.5	5
24	An international survey of imaging practices in radiotherapy. Physica Medica, 2021, 90, 53-65.	0.7	12
25	In Reply to Al-Rashdan. International Journal of Radiation Oncology Biology Physics, 2021, 111, 578.	0.8	0
26	TARGIT-R (Retrospective): 5-Year Follow-Up Evaluation of Intraoperative Radiation Therapy (IORT) for Breast Cancer Performed in North America. Annals of Surgical Oncology, 2021, 28, 2512-2521.	1.5	31
27	Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 58-67.	1.3	11
28	Patterns of Care and Outcomes for Small Cell Carcinoma of the Cervix: A National Retrospective Analysis of 542 Cases. Advances in Radiation Oncology, 2020, 5, 412-418.	1.2	4
29	Prognostic Significance of Nuclear Factor Kappa B Expression in Locally Advanced Cervical Cancer Patients Treated Definitively With Concurrent Chemoradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 47-51.	1.3	5
30	Addressing the Impact of Systemic Racism in Radiation Oncology. Advances in Radiation Oncology, 2020, 5, 791-792.	1.2	1
31	American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Criteria (AUC) Systematic Review and Guidelines for Operable Esophageal Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, E31.	0.8	0
32	Executive summary of the American Radium Society $\hat{A}^{\text{o}}$ Appropriate Use Criteria for management of uterine carcinosarcoma. Gynecologic Oncology, 2020, 158, 460-466.	1.4	9
33	Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations. Gynecologic Oncology, 2020, 158, 244-253.	1.4	29
34	Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. Journal of Clinical Oncology, 2020, 38, 1685-1692.	1.6	86
35	Abstract P4-12-21: Implementing a real-time magnetic resonance imaging guided accelerated partial breast irradiation program., 2020,,.		0
36	Radiation Therapy in Endometrial Cancer. , 2019, , 1-16.		0

#	Article	IF	CITATIONS
37	The Impact of Transitioning to Prospective Contouring and Planning Rounds as Peer Review. Advances in Radiation Oncology, 2019, 4, 532-540.	1.2	9
38	Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 591-605.	0.8	5
39	Executive Summary of the American Radium Society Appropriate Use Criteria for Local Excision in Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 977-993.	0.8	6
40	Salvage treatment in recurrent endometrial cancer of the pelvis and peritoneal cavity. Gynecologic Oncology Reports, 2019, 29, 1-6.	0.6	5
41	Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. New England Journal of Medicine, 2019, 380, 2317-2326.	27.0	326
42	Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. Gynecologic Oncology, 2019, 154, 183-188.	1.4	13
43	Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer. Journal of Clinical Oncology, 2019, 37, 1810-1818.	1.6	229
44	Thank you to those who Peer Reviewed in 2018 for Advances in Radiation Oncology. Advances in Radiation Oncology, 2019, 4, 211-217.	1.2	0
45	Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions. Advances in Radiation Oncology, 2019, 4, 103-111.	1.2	6
46	Impact on treatment time of MRI-based brachytherapy in two implants (4 doses) compared with CT-based brachytherapy in five implants for cervical cancer. Brachytherapy, 2019, 18, 141-145.	0.5	1
47	Ripk3 Signaling Regulates Hematopoietic Stem Cell Number and Function during Stress. Blood, 2019, 134, 3714-3714.	1.4	0
48	A Medicare cost analysis of MRI- versus CT-based high-dose-rate brachytherapy of the cervix: Can MRI-based planning be less costly? Brachytherapy, 2018, 17, 326-333.	0.5	6
49	The Relationship Between â€ <sup>*</sup> Body Mass Index and Sexual Function in Endometrial Cancer. Oncology Nursing Forum, 2018, 45, 25-32.	1.2	3
50	Advanced small cell carcinoma of the cervix $\hat{a}\in$ Successful treatment with concurrent etoposide and cisplatin chemotherapy and extended field radiation: A case report and discussion. Gynecologic Oncology Reports, 2018, 23, 4-6.	0.6	6
51	Out of the Basement and Into the Classroom: Pathways for Expanding the Role of Radiation Oncologists in Medical Student Education. Journal of the American College of Radiology, 2018, 15, 1620-1623.	1.8	30
52	Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1069-1077.	0.8	19
53	Targeted Intraoperative Radiation Therapy—A Promising Option for Accelerated Partial Breast Irradiation. JAMA Oncology, 2018, 4, 767.	7.1	0
54	Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer. Gynecologic Oncology, 2018, 148, 437-438.	1.4	2

#	Article	IF	Citations
55	Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 396-401.	1.3	28
56	Dilator Use After Vaginal Brachytherapy for Endometrial Cancer. Cancer Nursing, 2018, 41, 200-209.	1.5	15
57	Expression of the DNA repair gene <i>MLH1</i> correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer, 2018, 124, 491-498.	4.1	5
58	Delineating the relationship between Point A prescription dose and pelvic lymph node doses in intracavitary high-dose-rate brachytherapy treatment of cervical cancer for use in low- and middle-income countries. Brachytherapy, 2018, 17, 201-207.	0.5	5
59	Early outcomes and impact of a hybrid IC/IS applicator for a new MRI-based cervical brachytherapy program. Brachytherapy, 2018, 17, 187-193.	0.5	16
60	Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database. Gynecologic Oncology, 2018, 148, 147-153.	1.4	20
61	Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology–RTOG 1203. Journal of Clinical Oncology, 2018, 36, 2538-2544.	1.6	231
62	Cost in perspective: direct assessment of American market acceptability of Co-60 in gynecologic high-dose-rate brachytherapy and contrast with experience abroad. Journal of Contemporary Brachytherapy, 2018, 10, 503-509.	0.9	14
63	Does adjuvant concurrent or sequential chemotherapy increase the radiation-related toxicity of vaginal brachytherapy for endometrial cancer patients?. Brachytherapy, 2018, 17, 929-934.	0.5	5
64	Providing MR Imaging for Cervical Cancer Brachytherapy: Lessons for Radiologists. Radiographics, 2018, 38, 932-944.	3.3	7
65	Comparison of dosimetric and clinical outcomes between short- and long-channel cylinder applicators for vaginal brachytherapy in intermediate- and high-risk endometrial cancer. Brachytherapy, 2018, 17, 673-679.	0.5	3
66	Can MRI-only replace MRI-CT planning with a titanium tandem andÂovoid applicator?. Brachytherapy, 2018, 17, 747-752.	0.5	1
67	Intraoperative Radiation "Boost―to the Surgical Resection Bed following Pancreaticoduodenectomy for a Borderline Resectable Pancreatic Carcinoma: A Case Report. Frontiers in Oncology, 2018, 8, 12.	2.8	1
68	Intraoperative Radiotherapy With INTRABEAM: Technical and Dosimetric Considerations. Frontiers in Oncology, 2018, 8, 74.	2.8	35
69	Editorial: Intraoperative Radiotherapy (IORT)—A New Frontier for Personalized Medicine as Adjuvant Treatment and Treatment of Locally Recurrent Advanced Malignancy. Frontiers in Oncology, 2018, 8, 234.	2.8	3
70	Cost in Perspective: Comparing Physician Theoretical Willingness-to-Pay with Actual Cost of Additional Shielding Required for Cobalt-60. Brachytherapy, 2018, 17, S37.	0.5	0
71	American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy, 2017, 16, 95-108.	0.5	66
72	c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 590-597.	1.3	22

#	Article	IF	CITATIONS
73	The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of low-dose-rate brachytherapy. Brachytherapy, 2017, 16, 68-74.	0.5	10
74	Clinical trials in low and middle-income countries $\hat{a}\in$ "Successes and challenges. Gynecologic Oncology Reports, 2017, 19, 5-9.	0.6	39
75	Spectral characterization of tissues in high spectral and spatial resolution MR images: Implications for a classificationâ€based synthetic CT algorithm. Medical Physics, 2017, 44, 1865-1875.	3.0	2
76	Commentary on "Accelerated partial breast irradiation consensus statement: Update of an ASTRO Evidence-Based Consensus Statement". Practical Radiation Oncology, 2017, 7, e159-e163.	2.1	9
77	Cervical cancer: A global health crisis. Cancer, 2017, 123, 2404-2412.	4.1	790
78	The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials. International Journal of Gynecological Cancer, 2017, 27, 813-818.	2.5	0
79	Adjuvant Chemoradiation Therapy for Cervical Cancer and Effect of Timing and Duration on Treatment Outcome. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1132-1141.	0.8	20
80	ACR Appropriateness Criteria® Resectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 109-117.	1.3	7
81	Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. Cancer, 2017, 123, 485-493.	4.1	24
82	Improved overall survival with adjuvant radiotherapy for high-intermediate and high risk Stage I endometrial cancer. Radiotherapy and Oncology, 2017, 122, 452-457.	0.6	20
83	Revisiting Milan cervical cancer study: Do the original findings hold in the era of chemotherapy?. Gynecologic Oncology, 2017, 144, 299-304.	1.4	3
84	American College of Radiology–American Brachytherapy Society practice parameter for electronically generated low-energy radiation sources. Brachytherapy, 2017, 16, 1083-1090.	0.5	7
85	Factors Associated with Willingness to Invest in a New HDR Isotope. Brachytherapy, 2017, 16, S38.	0.5	0
86	Reducing Prostate High Dose Rate Brachytherapy Treatment Planning Duration Through Targeted Interventions. Brachytherapy, 2017, 16, S40.	0.5	0
87	Comparing Low Dose Rate and High Dose Rate Prostate Brachytherapy Implant Dosimetry. Brachytherapy, 2017, 16, S113-S114.	0.5	1
88	A national survey of HDR source knowledge among practicing radiation oncologists and residents: Establishing a willingness-to-pay threshold for cobalt-60 usage. Brachytherapy, 2017, 16, 910-915.	0.5	4
89	Resisting RECIST—Uniformity Versus Clinical Validity. International Journal of Gynecological Cancer, 2017, 27, 1619-1627.	2.5	1
90	Adaptive Radiotherapy for Head and Neck Cancer. Technology in Cancer Research and Treatment, 2017, 16, 218-223.	1.9	53

#	Article	IF	Citations
91	Cervical Cancer: A Global Health Crisis. Obstetrical and Gynecological Survey, 2017, 72, 654-655.	0.4	4
92	External beam techniques to boost cervical cancer when brachytherapy is not an optionâ€"theories and applications. Annals of Translational Medicine, 2017, 5, 207-207.	1.7	32
93	Intraoperative Radiotherapy for Breast Cancer. Frontiers in Oncology, 2017, 7, 317.	2.8	42
94	How one institution overcame the challenges to start an MRI-based brachytherapy program for cervical cancer. Journal of Contemporary Brachytherapy, 2017, 2, 177-186.	0.9	17
95	Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World Journal of Hepatology, 2017, 9, 645.	2.0	9
96	Agreement validation between axial imaging modalities and endoscopic ultrasonography in staging resectability of pancreatic cancer Journal of Clinical Oncology, 2017, 35, 273-273.	1.6	2
97	Analysis of adjuvant chemotherapy and radiotherapy for stage II endometroid type endometrial cancer Journal of Clinical Oncology, 2017, 35, e17118-e17118.	1.6	0
98	Abstract 3019: The role of TACC3 in the progression from ductal carcinoma in situ to invasive breast cancer. , $2017$ , , .		1
99	Combined modality therapy in the adjuvant treatment of uterine serous carcinoma. Journal of Gynecologic Oncology, 2016, 27, e13.	2.2	1
100	Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. Journal of Global Oncology, 2016, 2, 311-340.	0.5	127
101	Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience. Journal of Gastrointestinal Cancer, 2016, 47, 196-201.	1.3	5
102	Predictors of post-treatment symptomatic pneumonitis in lung SBRT patients through decision tree analysis. Journal of Radiation Oncology, 2016, 5, 273-278.	0.7	2
103	Point A vs. HR-CTV D90 in MRI-based cervical brachytherapy of small and large lesions. Brachytherapy, 2016, 15, 825-831.	0.5	9
104	Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? A population based study. Gynecologic Oncology, 2016, 143, 539-544.	1.4	13
105	Prospective Case Review in Radiation Oncology Prior to Treatment Delivery. Oncology Times, 2016, 38, 1,14-15.	0.1	0
106	Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Expert Review of Anticancer Therapy, 2016, 16, 523-530.	2.4	28
107	Consensus Recommendations for Radiation Therapy Contouring and Treatment ofÂVulvarÂCarcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1191-1200.	0.8	83
108	Bladder distension improves the dosimetry of organs at risk duringÂintracavitary cervical high-dose-rate brachytherapy. Brachytherapy, 2016, 15, 30-34.	0.5	10

#	Article	IF	Citations
109	ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy. Journal of the American College of Radiology, 2016, 13, 265-273.	1.8	9
110	Vaginal brachytherapy for postoperative endometrial cancer: 2014 Survey of the American Brachytherapy Society. Brachytherapy, 2016, 15, 23-29.	0.5	58
111	Image Guided Cervical Brachytherapy: 2014 Survey of the American Brachytherapy Society. International Journal of Radiation Oncology Biology Physics, 2016, 94, 598-604.	0.8	104
112	Decision Trees Predicting Tumor Shrinkage for Head and Neck Cancer. Technology in Cancer Research and Treatment, 2016, 15, 139-145.	1.9	34
113	Moving towards hospital and radiation oncology EMR integration: Results of an institutional survey Journal of Clinical Oncology, 2016, 34, 152-152.	1.6	0
114	In Regard to Hepel and Wazer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 955-957.	0.8	2
115	NRG Oncology <i>/</i> RTOG 0921: A phase 2 study of postoperative intensityâ€modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer, 2015, 121, 2156-2163.	4.1	47
116	Clinical outcomes with the MammoSite radiation therapy system: results of a prospective trial. Journal of Radiation Oncology, 2015, 4, 395-400.	0.7	4
117	The role of vaginal cuff brachytherapy in endometrial cancer. Gynecologic Oncology, 2015, 136, 365-372.	1.4	32
118	RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation. Journal of Clinical Oncology, 2015, 33, 709-715.	1.6	329
119	Image-Based Brachytherapy for the Treatment of Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 921-934.	0.8	61
120	Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. Brachytherapy, 2015, 14, 587-599.	0.5	93
121	The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup. International Journal of Radiation Oncology Biology Physics, 2015, 92, 506-508.	0.8	12
122	Radiation Oncology Resident In-Training Examination. International Journal of Radiation Oncology Biology Physics, 2015, 92, 532-535.	0.8	7
123	Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer. Breast, 2015, 24, 418-425.	2.2	40
124	Contouring Guidelines for the Axillary Lymph Nodes for the Delivery of Radiation Therapy in Breast Cancer: Evaluation of the RTOG Breast Cancer Atlas. International Journal of Radiation Oncology Biology Physics, 2015, 93, 257-265.	0.8	54
125	Single Administration of p2TA (AB103), a CD28 Antagonist Peptide, Prevents Inflammatory and Thrombotic Reactions and Protects against Gastrointestinal Injury in Total-Body Irradiated Mice. PLoS ONE, 2014, 9, e101161.	2.5	11
126	Incidence of Minimally Invasive Colorectal Cancer Surgery at National Comprehensive Cancer Network Centers. Journal of the National Cancer Institute, 2014, 107, dju362-dju362.	6.3	48

#	Article	IF	CITATIONS
127	Intraoperative radiation therapy techniques and options for breast cancer. Expert Review of Medical Devices, 2014, 11, 265-273.	2.8	10
128	The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation Oncology evidence-based guideline. Practical Radiation Oncology, 2014, 4, 137-144.	2.1	151
129	Comparison and Consensus Guidelines for Delineation of Clinical Target Volume for CT- and MR-Based Brachytherapy in Locally Advanced Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 320-328.	0.8	154
130	Using Intensity-Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report. Tumori, 2013, 99, e38-e42.	1.1	5
131	Differences in breast aesthetic outcomes due to radiation: A validated, quantitative analysis of expander-implant reconstruction. Canadian Journal of Plastic Surgery, 2013, 21, 73-77.	0.3	9
132	The Quality of Cervical Cancer Brachytherapy Implantation and the Impact on Local Recurrence and Disease-Free Survival in Radiation Therapy Oncology Group Prospective Trials 0116 and 0128. International Journal of Gynecological Cancer, 2012, 22, 123-131.	2.5	100
133	A Phase II Study of Intensity Modulated Radiation Therapy to the Pelvis for Postoperative Patients With Endometrial Carcinoma: Radiation Therapy Oncology Group Trial 0418. International Journal of Radiation Oncology Biology Physics, 2012, 84, e23-e28.	0.8	83
134	American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy, 2012, 11, 58-67.	0.5	222
135	S100A4 as a biomarker of resistance to gemcitabine: A secondary analysis of RTOG 9704 Journal of Clinical Oncology, 2012, 30, 165-165.	1.6	0
136	Extended-Field Irradiation and Intracavitary Brachytherapy Combined With Cisplatin and Amifostine for Cervical Cancer With Positive Para-Aortic or High Common Iliac Lymph Nodes. International Journal of Gynecological Cancer, 2011, 21, 1.	2.5	25
137	Phase II Trial of Full-Dose Gemcitabine and Bevacizumab in Combination With Attenuated Three-Dimensional Conformal Radiotherapy in Patients With Localized Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 476-482.	0.8	52
138	Should Uterine Tandem Applicators Ever Be Placed Without Ultrasound Guidance? No. International Journal of Gynecological Cancer, 2011, 21, 941-944.	2.5	47
139	Repair of Massive Ventral Hernias with the Separation of Parts Technique: Reversal of the †Lost Domain'. American Surgeon, 2009, 75, 301-306.	0.8	27
140	Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 428-434.	0.8	349
141	Extended-Field Irradiation and Intracavitary Brachytherapy Combined With Cisplatin Chemotherapy for Cervical Cancer With Positive Para-Aortic or High Common Iliac Lymph Nodes: Results of ARM 1 of RTOG 0116. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1081-1087.	0.8	130
142	American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: Current status of vaginal brachytherapy. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1502-1507.	0.8	89
143	Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the radiation therapy oncology group C-0116 trial. Seminars in Oncology, 2003, 30, 68-71.	2.2	9
144	The potential role of amifostine in the treatment of carcinoma of the uterine cervix: A review. Seminars in Radiation Oncology, 2002, 12, 68-74.	2.2	3

#	Article	IF	CITATIONS
145	Potential for use of amifostine in cervical cancer. Seminars in Oncology, 2002, 29, 34-37.	2.2	51